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Abstract
Background: Effective, accessible, and affordable depression treatment is of high importance considering the large
personal and economic burden of depression. Internet-based treatment is considered a promising clinical and cost-
effective alternative to current routine depression treatment strategies such as face-to-face psychotherapy. However,
it is not clear whether research findings translate to routine clinical practice such as primary or specialized mental
health care. The E-COMPARED project aims to gain knowledge on the clinical and cost-effectiveness of blended
depression treatment compared to treatment-as-usual in routine care.
Methods/design: E-COMPARED will employ a pragmatic, multinational, randomized controlled, non-inferiority trial
in eight European countries. Adults diagnosed with major depressive disorder (MDD) will be recruited in primary
care (Germany, Poland, Spain, Sweden, and the United Kingdom) or specialized mental health care (France, The
Netherlands, and Switzerland). Regular care for depression is compared to “blended” service delivery combining
mobile and Internet technologies with face-to-face treatment in one treatment protocol. Participants will be
followed up at 3, 6, and 12 months after baseline to determine clinical improvements in symptoms of depression
(primary outcome: Patient Health Questionnaire-9), remission of depression, and cost-effectiveness. Main analyses
will be conducted on the pooled data from the eight countries (n = 1200 in total, 150 participants in each country).
Discussion: The E-COMPARED project will provide mental health care stakeholders with evidence-based
information and recommendations on the clinical and cost-effectiveness of blended depression treatment.
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Background
Depression is a common mental disorder with a negative
impact on mental well-being, quality of life, and social
and work-related functioning both in the short and lon-
ger term [1]. Additionally, depression is associated with
increased morbidity, mortality, health care utilization,
and health care costs [2–4]. On a population level,
depression is one of the most costly diseases. In the
European Union, 30 million citizens are affected by de-
pression and the economic costs of depression were esti-
mated at €92 billion in 2010 and are still rising [5, 6].
The majority of these costs is caused by lost productivity
[5]. In combination with the fact that depression is
highly prevalent among the working-age population [7],
depression poses a significant societal and economic
burden to European society.
Depression can be treated effectively with pharmaco-
logical treatment, psychotherapy, especially cognitive-
behavioral therapy (CBT), or a combination of both [8–12].
Antidepressants are widely prescribed, both in primary and
specialized mental health care settings, while non-
pharmacologic treatments, such as psychotherapeutic inter-
ventions, are offered to a lesser degree in most of Europe,
and are virtually absent in primary care in some countries
such as Portugal [13]. Moreover, despite the availability of
effective treatments, the proportion of adults with de-
pression who actually seek or receive treatment is lim-
ited with estimates ranging between 35 and 45 % in
higher-income countries [14, 15] indicating that the
treatment of depression leaves ample room for im-
provement. Thus, European health care systems face
the challenge of improving access to cost-effective
treatments to relieve the burden of depression [16].
Internet-based depression treatment is considered a
promising clinical and cost-effective alternative to
current routine depression treatment strategies such as
face-to-face psychotherapy. Ample research has demon-
strated the clinical effectiveness of Internet-based treat-
ment for depression when delivered with minimal
guidance in controlled research settings [17] with effect
sizes that are comparable to face-to-face interventions
[18]. It is also unclear whether Internet-based depression
treatments are cost-effective, which is considered an im-
portant next step in research [19]. In addition, it is not
yet clear to what extent these findings translate to rou-
tine clinical practice such as primary care or specialized
mental health care. The patient populations in these set-
tings are more heterogeneous than those in controlled
research settings and the delivery of services in these set-
tings is more complex.
Blended depression treatment is a relatively new treat-
ment format where online and face-to-face interventions
are integrated into one treatment protocol [20, 21].
Blended depression treatment formats are of particular
interest to primary and specialized treatment centers for
several reasons [22, 23]. Patients often present with
complex clinical problems and may need more intensive
guidance than Internet-based treatments alone are able
to offer [24]. Blended treatment delivery would allow
therapists to focus on process-related treatment compo-
nents during the face-to-face sessions, such as patient-
specific needs, discussion of thoughts and feelings, and
treatment evaluation, while more practical therapy as-
pects can be delivered in the online sessions (e.g., psy-
choeducation, homework, and symptom monitoring)
[25, 26]. In addition, treatment in specialized mental
health care settings is costly. Both in primary and spe-
cialized mental health care, patients often return for
follow-up consultations which provides an opportunity
to introduce blended treatments. It is expected that im-
plementation of blended Internet-based treatments may
reduce the number of face-to-face sessions needed while
mental health gains remain the same or even increase.
Thus, there are a number of advantages associated with
blended depression treatment which may improve the
efficiency of the health care system on the whole if these
are implemented on a wider scale.
Comparative effectiveness research (CER) is designed to
inform health care decisions with the aim of improving
patient outcomes, quality of life, and cost-containment.
The overall objective of E-COMPARED is to provide men-
tal health care stakeholders, including patients, health care
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professionals, health insurers, mental health service pro-
viders, and policy-makers, with evidence-based informa-
tion and recommendations about the clinical effectiveness
and cost-effectiveness of blended depression treatment in
comparison with treatment-as-usual (TAU) in Europe.
The study will be conducted in eight European countries
with different diversities and geographical spread includ-
ing countries that are frontrunners in the field of Internet-
based treatments (The Netherlands, Sweden, and the
United Kingdom (UK)), countries in which the field has
been evolving rapidly (Germany, Spain, and Switzerland),
and countries with very little expertise and experience in
this area (France and Poland). Thus, the outcome of the
project will take into account these different situations
and the results will inform the routine practice of spe-
cific mental health service organizations in Europe. The
aim of this paper is to describe the protocol of the
multinational study that evaluates the effectiveness and
cost-effectiveness of blended cognitive behavioral therapy
(bCBT) for adults with major depressive disorder (MDD)
in comparison with TAU in Europe both in primary and
specialized mental health care settings. It is hypothesized
that bCBT is clinically non-inferior (i.e., not less effective)
as compared to TAU, but that it is cost-effective since we
expect that less therapist time is needed to deliver treat-
ment resulting in lower treatment costs.
Method/design
Design
This is a two-arm, randomized controlled, non-inferiority
trial, with an economic evaluation alongside, in eight
countries in Europe (France, Germany, The Netherlands,
Poland, Spain, Sweden, Switzerland, and the UK). The
non-inferiority design was chosen to test whether bCBT is
not less effective than TAU [27]. The trials will be con-
ducted in routine primary care (sites: Germany, Poland,
Spain, Sweden, and the UK) or specialized mental health
care (sites: France, The Netherlands, and Switzerland). Re-
spondents in both conditions will be followed until
12 months after baseline (measures will be taken at base-
line, 3 months, 6 months, and 12 months).
Participants
Recruitment procedures are country- and setting-
specific (see Table 1). See Fig. 1 for the flow of pa-
tients through the study and attachments (Additional
files 1 and 2) for an overview of study procedures
and a checklist in line with Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
[28]. In all countries, the following inclusion and ex-
clusion criteria will be applied uniformly.
Inclusion criteria: (1) being 18 years of age or older,
(2) meeting Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) diagnostic criteria for MDD as
confirmed by the telephone-administered MINI Inter-
national Neuropsychiatric Interview (M.I.N.I) version 5.0
[29], and (3) minimal to severe symptoms of depression
based on a score of 5 or higher on the Patient Health
Questionnaire-9 (PHQ-9) screening questionnaire [30].
Exclusion criteria: (1) current high risk for suicide
according to the M.I.N.I. interview section C, (2) psy-
chiatric comorbidity: substance dependence, bipolar
affective disorder, psychotic illness, obsessive compul-
sive disorder, as established during the M.I.N.I. inter-
view, (3) currently receiving psychological treatment
for depression in primary or specialized mental health
care, (4) being unable to comprehend the spoken and
written language of the country where the study is
conducted (i.e., Dutch in The Netherlands, German
in Germany, English in the UK, Polish in Poland,
Swedish in Sweden, German in Switzerland, French
in France, and Spanish in Spain), (5) not having ac-
cess to a computer with fast Internet connection (i.e.,
broadband or comparable), and (6) not having a
smartphone that is compatible with the mobile com-
ponent of the intervention that is offered, or not will-
ing to carry a smartphone if one is provided with
one by the research team for the study duration.
Table 1 Recruitment procedure and treatment setting per country
Country Treatment setting Recruitment procedure
FR Specialized mental
health care
New or regular patients recruited
through cognitive behavioral therapy
(CBT) therapists from 11 expert
centers throughout France
DE Primary care Recruitment in the waiting room
of general practices
NL Specialized mental
health care
New patients recruited through mood
disorder departments of three
outpatient clinics in Amsterdam
and Leiden
PL Primary care Recruitment through primary mental
health care centers and therapists
trained at postgraduate CBT
programs conducted in five major
cities (Warsaw, Sopot, Poznan,
Katowice, and Wroclaw)
ESP Primary care Recruitment through several primary
care centers of patients who report
to the GP with depression
SE Primary care Recruitment through routine primary
care clinics in Stockholm and Linköping
CH Specialized mental
health care
Recruitment through two outpatient
clinics (Bern and Zurich) and individual
therapists
UK Primary care Recruitment through the NHS program
“Improving Access to Psychological
Therapies (IAPT)” in the London region.
IAPT is a service to increase primary
mental health care offering low-intensity
treatment to GP-registered adults
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Sample size calculation
The sample size calculation is based on the non-
inferiority design and calculated for the primary clin-
ical outcome, symptoms of depression at 3 months
after baseline. The non-inferiority margin was set at
Cohen’s d = 0.20 which is a conservative estimate of
the subjective minimal important difference that is
noticeable by depressed patients [31]. To test the hy-
pothesis that bCBT is not inferior to TAU, a total of
1052 patients is required. With this number of pa-
tients we are 90 % certain (power of .90) that the
lower limit of the two-sided 95 % confidence interval
will truly be above the non-inferiority limit Cohen’s d
= −0.20. To allow for expected study dropout and
variation between settings the total number of partici-
pants to be recruited will be 1200, 150 patients in
each country.
Randomization
Randomization will be conducted centrally by the (PI)
organization (VU Amsterdam) by a team of independent
researchers (the randomization team). The randomization
team allocates patients to treatment in all countries except
for France where the allocation process will be automated
and the UK where the allocation process will be out-
sourced to a local independent researcher as for logistical
reasons the randomization outcome should be instantly
available. Randomization will take place at an individual
level, stratified by country, after the eligibility and baseline
assessment. Further stratification on recruitment location
will be applied in France (11 centers), Switzerland (3 cen-
ters), The Netherlands (3 centers), and Sweden (two cit-
ies). The randomization team will create the allocation
scheme with a computerized random number generator
(Random Allocation Software) at an allocation ratio of 1:1.
--
-
-
--
-
-
Fig. 1 Flow of participants through the trial
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Block randomization will be used with variable block sizes
that vary between 8 and 14 allocations per block (in
France block sizes of 2 and 4 will be applied because of
the large number of strata). Subjects will be randomized
into two groups: bCBT or TAU. All investigators and cli-
nicians will be unknown to the randomization scheme.
Blinding for treatment allocation is not possible as it will
be clear to both therapists and patients whether the treat-
ment is blended or not. However, outcome assessors will
be blinded.
Assessment measures
An overview of the measures and the time of assessment
is provided in Table 2. All questionnaire measures are
completed online.
Primary outcome
The primary outcome measure is symptoms of depres-
sion as assessed with the Patient Health Questionnaire-9
(PHQ-9) at 3 months [30]. The PHQ-9 is a multipurpose
instrument that was developed for use in primary care
but has been validated in different patient populations
such as primary care, the general population, specialized
mental health care, and patients with somatic disease
[32, 33]. The questionnaire is used frequently in clinical
trials to assess the outcomes of treatment [34]. The nine
items are each scored on a 0–3 scale with the total score
ranging from 0–27 and higher scores indicating more
severe depression. The PHQ-9 has been shown to have
good psychometric properties [32, 33].
Secondary outcomes
The 16-item self-report version of the Quick Inventory
of Depressive Symptomatology Self-Report (QIDS-SR)
[35] will be used in addition to the PHQ-9 to measure
symptoms of depression. The patient QIDS-SR consists
of 16 items (each item scores 0–3) and includes symp-
tom domains of MDD based on the DSM-IV. The
QIDS-SR has shown good psychometric properties in
several clinical populations [34].
A diagnosis of depression will be established with the
M.I.N.I. International Neuropsychiatric Interview (M.I.N.I.)
version 5.0. The M.I.N.I. is a structured diagnostic interview
based on the DSM-IV and the International Classification
of Diseases (ICD-10) criteria. The M.I.N.I. has been trans-
lated to 65 languages and is used for both clinical and re-
search practice. The interview compares well with the
Structural Clinical Interview for DSM-IV Disorders (SCID)
[29] and the Composite International Diagnostic Interview
(CIDI) [29, 36]. The full M.I.N.I. 5.0, with exception of sec-
tions M (Anorexia nervosa), N (Bulimia nervosa), and P
(Antisocial personality disorder), will be administered at
baseline to assess lifetime and current depression, and
current comorbid disorders that often co-occur with and
predict the onset of depression (anxiety disorders and post-
traumatic stress disorder; PTSD), and other comorbid dis-
orders that are an exclusion criteria in this study (i.e.,
substance dependence, bipolar affective disorder, psychotic
illness, and obsessive compulsive disorder). At the 12-
month follow-up, the depression, anxiety and PTSD
sections will be administered again to assess recovery of de-
pression and status of the frequently co-occurring disorders
of anxiety and PTSD.
Quality of life will be assessed with the EQ-5D-5L
[37]. The EQ-5D-5L is a self-report questionnaire which
measures health-related quality of life and enables
Table 2 Overview of measures
Variable Instrument Screening
Baseline
3 months 6 months 12
months
Questions taken from patients
Demographics X
Current
treatment
X
Diagnostic
interview
M.I.N.I. X X
Depressive
symptoms
PHQ-9
and QIDS-
SR16
X X X X
Quality of life EQ-5D-5L X X X X
Societal costs TIC-P X X X X
Treatment
preference
X
Patient
expectancy
CEQ X
Working
alliance
WAI-SF Xc
Technology
alliance
TAI-OTa Xc
Client
satisfaction
CSQ Xc
Satisfaction
with the online
program
SUSa Xc
Questions taken from therapists
Working
alliance
WAI-SF Xc
Satisfaction
with the online
program
SUSa,b Xc
aOffered to condition receiving blended treatment only
bHas to be completed once per therapist after completion of the
first treatment
cQuestionnaires may be taken at 6 months when the duration of treatment is
longer than 3 months
CEQ Credibility and Expectancy Questionnaire, CSQ Client Satisfaction
Questionnaire-8, EQ-5D-5L EuroQol 5 dimensions 5 levels, M.I.N.I. MINI
International Neuropsychiatric Interview, PHQ-9 Patient Health Questionnaire-9,
QIDS-SR16 Quick Inventory of Depressive Symptomatology, SUS System
Usability Scale, TAI-OT Technology Alliance Inventory-Online Therapy, TIC-P
Trimbos and iMTA Questionnaires on Costs Associated with Psychiatric Illness,
WAI-SF Work Alliance Inventory short form
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conversion to utility scores to calculate quality-adjusted
life years (QALYs). The EQ-5D-5L consists of five di-
mensions: mobility, self-care, ordinary activities, discom-
fort, and mood state related to anxiety or depression.
For each dimension there are five severity levels defined
ranging from no problems to many problems [38]. The
EQ-5D-5L has been translated into more than 100 dif-
ferent language versions. The EQ-5D-5L health states
will be converted to utility scores using country-specific
preference weights if available. Otherwise, the UK pref-
erence weights will be used. QALYs will be calculated by
multiplying the utilities with the amount of time a pa-
tient has spent in a particular health state. Transitions
between health states will be linearly interpolated.
Cost measures
Costs will be measured from a societal perspective.
Health service uptake, use of informal care, and lost
productivity due to illness will be measured with an
adapted version of the Trimbos and iMTA Question-
naires on Costs Associated with Psychiatric Illness (TiC-
P) [39]. The TiC-P is a self-report questionnaire and
consists of two different parts that can be administered
separately. Part I will be used to assess the participants’
health care utilization and medication use. Part II (short
form Health and Labor Questionnaire; SF-HLQ) mea-
sures lost productivity costs resulting from absenteeism
(being absent from work because of illness) and present-
eeism (being present at work while ill which may lead to
reduced efficiency), and consists of 11 items. Health care
utilization, use of informal care, and productivity losses
will be valued using country-specific opportunity costs.
Other assessments
Several demographic variables, history of treatment for
mental health problems, and treatment preferences will
be measured at baseline.
The therapeutic alliance between therapists and pa-
tients will be assessed with the short version of the
Working Alliance Inventory short form (WAI-SF). The
WAI-SF is a 12-item self-report questionnaire with re-
sponses on a 5-point Likert scale ranging from 1 (never)
to 5 (always) [40]. The questionnaire covers three di-
mensions of working alliance: (1) therapeutic goals, (2)
tasks, and (3) bond, and the subscales have been shown
to have good internal consistencies. Both the patient and
the 10-item therapist version of the questionnaire will be
administered at 3-month follow-up. The alliance be-
tween the patient and technologies will be assessed with
the WAI Online Therapy questionnaire developed by
Labpsitec (http://www.labpsitec.uji.es/esp/index.php) at
3-month follow-up.
Patients’ expectancy of treatment will be assessed with
the credibility and expectancy questionnaire (CEQ) of
Devilly and Borkovec [41] at baseline. Both factors (cred-
ibility and expectancy) have been shown to be stable
across different populations with high internal
consistency within each factor. The scale consists of six
questions, with answer options rated on a 10-point scale
and on a 1–100 % scale.
Patient’s satisfaction with the treatment will be
assessed with the Client Satisfaction Questionnaire-8
(CSQ-8) [42]. This questionnaire has been translated
into multiple languages and is used to measure global
patient satisfaction. The questionnaire consists of eight
items that are measured on a 4-point scale with total
scores ranging from 8 to 32 and has shown good psy-
chometric properties.
Satisfaction with the platform will be evaluated with
the System Usability Scale (SUS) [43]. The SUS is a 10-
item questionnaire giving a global view of subjective as-
sessments of usability of a technology system. All items
are measured on a 5-point scale ranging from strongly
disagree to strongly agree. Total SUS scores have a range
from 0–100. The questionnaire was found to be reliable
and robust [44].
Treatment
bCBT
The blended depression treatment in this study com-
bines individual face-to-face CBT with CBT delivered
through an Internet-based treatment platform with
mobile phone components (either integrated in the
treatment platform or as a separate system). The core
components of the bCBT treatment are: (1) psychoedu-
cation, (2) cognitive restructuring, (3) behavioral activa-
tion, and (4) relapse prevention. These will be delivered
over 11–20 sessions (see Table 3). Traditional CBT treat-
ment consists mostly of face-to-face sessions. In our
bCBT treatment, the number of face-to-face sessions is
reduced and replaced by online treatment modules. In
Table 3 Overview of blended treatment applied in each
country
Country Platform Duration Online/face-to-face Sequencing
FRa Moodbuster 16 wks 8/8 Alternate
DEa Moodbuster 10–13 wks 10/5 Alternate
NLa Moodbuster 20 wks 10/10 Alternate
PLa Moodbuster 6–10 wks 6/7 Alternate
ESPb Smiling is fun 10 wks 8/3 1-4-1-4-1
SE Iterapi 12 wks 8/4 Alternate
CHc Deprexis 18 wks 9/9 Alternate
UKa Moodbuster 11 wks 5/6 Alternate
aAdditional module on physical exercise, and problem solving
bAdditional module on coping skills
cAdditional modules on mindfulness, interpersonal skills, positive psychology,
emotion-focused therapy, and childhood experiences
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this study, the ratio between the number of face-to-face
sessions and the number of online modules may vary ac-
cording to practice in participating countries, but a
minimum of one third of the sessions should be face-to-
face and a minimum of one third of the sessions should
be provided online. Thus, for example, when the number
of face-to-face sessions is 6, the number of online
sessions lies between 3 and 12. bCBT may also include
additional components such as mindfulness, coping
skills training or problem solving, but these additional
components cannot take up more than a quarter of the
total treatment (no more than about 25 % of the face-to-
face and online sessions combined). This is to prevent
too much heterogeneity in the treatment programs.
bCBT will be provided by CBT therapists who will re-
ceive training on how to deliver the treatment. CBT
therapists will either be licensed CBT therapists, CBT
therapists in training who work under supervision of an
experienced licensed CBT therapist in specialized mental
health care, or licensed psychologists, or psychologists in
training who work under supervision of a licensed
psychologist with a CBT orientation in primary care.
Internet platforms applied in this study
Various platforms are used in this study, tailored to the
needs of local sites (see Table 3). All Internet platforms
include: (1) a web-based interface providing the patients’
access to online CBT, (2) a mobile phone component
which enables daily monitoring of mood state, cogni-
tions, activities, social interaction, and sleep (Ecological
Momentary Assessment; EMA). The mobile measures
will be time and date stamped.
Treatment fidelity
To ensure treatment fidelity: (1) a detailed bCBT treat-
ment manual is available at each site to guide therapists
through the treatment, (2) regular contacts are organized
between the therapists and the research team to prevent
drift of the treatment protocols within each country, and
(3) therapists register the number of sessions, the fre-
quency of the sessions, the main strategies used in each
session, the duration of each contact, and whether they
have referred the patient to the online part of the treat-
ment. Therapist activities on the platform will be
assessed through track and change functionalities to
measure, for example, the number of logins and type of
activity in each country (log files). In some countries,
therapists deliver both treatments (bCBT and TAU), be-
cause there are not sufficient therapists available in the
partaking country (i.e., France) or the intake procedure
does not allow a change of therapist after randomization
(i.e., The Netherlands, and Switzerland). Thus, in these
countries the therapist conducting the intake will also be
the therapist providing the treatment. Contamination
between blended depression treatment and TAU is not
an insurmountable problem in this study as the contents
of the face-to-face treatments may be similar and the
participants in the TAU condition do not have access to
the Internet-based treatment. Patients are allowed to re-
ceive pharmacotherapy in addition to the bCBT if
deemed necessary by the health care professional since
this reflects routine clinical practice in both treatment
conditions.
TAU
TAU is defined as the routine care that subjects receive
when they are diagnosed with depression in the specific
treatment setting where they are recruited. In practice,
this means that TAU may vary between countries, treat-
ment setting, and among patients (see Table 1) and is
likely to include pharmacologic treatment, psychother-
apy or a combination of both. We will not interfere with
TAU but we will monitor carefully which health care
services are utilized by TAU patients using patient
records and through self-report (including TIC-P
measurements).
Statistical approach
Data from the eight trials will be combined and multiple
imputation will be used to deal with missing data.
Intention-to-treat analyses (ITT) increase the risk of
type I errors in non-inferiority trials and per-protocol
analyses are preferred over ITT analyses [27]. Therefore,
the main analysis will consist of a per-protocol analysis
meaning that only those patients who have completed
the treatment will be included in the analyses. ITT ana-
lyses will be used in sensitivity analyses to increase
confidence in the results obtained by including all par-
ticipants in the analyses independent of whether they
completed the treatment or not. Multilevel regression
analyses will be applied for both types of analyses, taking
into account the differences between countries. Time of
assessment will be treated as a fixed variable to examine
the difference between groups on each occasion of
measurement. Regarding the primary outcome, symp-
toms of depression, bCBT is considered non-inferior as
compared with TAU when the two-sided 95 % confi-
dence interval (the range of plausible differences
between the two treatments) lies entirely above the
standard mean difference of −0.20 which is the non-
inferiority margin and the smallest clinically acceptable
difference. Cohen’s d will be calculated to determine the
magnitude of the treatment effects for continuous out-
come measures, both within groups for each timepoint
compared to baseline, and between groups. Effect sizes
under <0.2 are deemed to be small, between 0.2 and 0.5
are deemed to be moderate, and >0.8 are deemed to be
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large. For dichotomous outcome measures, we will cal-
culate the relative risk ratio.
Economic evaluation
The economic evaluation will be first conducted on a time
horizon corresponding to the trial horizon. In a second,
time modeling cost-effectiveness on a longer period (a 5-
year horizon) will be considered. The analysis will be per-
formed both from the societal perspective and a health
care cost perspective. Multiple imputation will be used to
impute missing cost and effect data. Bivariate regression
models will be used to estimate cost and effect differences
while adjusting for potential confounders [45]. Incremen-
tal cost-effectiveness ratios (ICERs) will be calculated by
dividing the mean difference in costs between bCBT and
TAU by the difference in effects. To account for the typic-
ally skewed distribution of costs, bias-corrected and accel-
erated bootstrapping (5000 replications) will be used to
estimate the 95 % confidence intervals around the mean
cost differences and the uncertainty surrounding the
ICERs. The bootstrapped ICERs will be graphically pre-
sented in cost-effectiveness planes [46]. Cost-effectiveness
acceptability curves [47] will be estimated to show the
probability that bCBT is cost-effective in comparison with
TAU for a range of different ceiling ratios, thereby show-
ing decision uncertainty.
Ethical issues
Ethical approval for the trials has been obtained locally
in each country. All participants provide written in-
formed consent before taking part in the trial and are
asked for their permission to share their (anonymized)
data across participating E-COMPARED partners and to
report on the results in publications. When data is
shared among the collaborating sites and countries it
will be encrypted and it will not contain identifiable in-
formation. The studies will be conducted in line with
the declaration of Helsinki [48] and each trial is regis-
tered in a local clinical trial register. All researchers will
follow the guidelines for Good Clinical Practice [49] and
the trial outcomes will be reported in line with the Con-
solidated Standards of Reporting Trials (CONSORT)
guidelines [50].
Discussion
European health care systems face the challenge of im-
proving access to cost-effective treatments to relieve the
burden of depression. Comparative effectiveness research
(CER) may be an appropriate method to provide evidence
for improved informed decision on depression treatment
with the aim to increase patient outcomes, quality of life,
and cost-containment. The E-COMPARED project aims
to examine the clinical and cost-effectiveness of bCBT for
adults with depression compared to TAU in eight
countries across Europe. It is expected that bCBT is clinic-
ally non-inferior compared to TAU, but that it is cost-
effective as less therapist time is needed to deliver
treatment.
This is one of the first trials to examine the effectiveness
of bCBT in routine primary and specialized mental health
care throughout Europe. So far, most studies have been
conducted in controlled research settings in individual
countries, and it is not clear how these findings translate
to routine “real-world” practice or how they differ between
health care systems. The E-COMPARED study is a large,
multinational, randomized controlled trial with sufficient
statistical power to take into account the heterogeneity be-
tween countries by pooling data. Comparison of bCBT
with TAU will inform how blended depression treatment
is related to current routine practice in different settings
and under different circumstances.
Research in routine practice is difficult as research pro-
cedures are often constrained by the complexity of the
service delivery centers and the patient population. There-
fore, pragmatic decisions (i.e., external validity) have to be
balanced against stringent research design requirements
(i.e., internal validity). We expect that research will be
even more complicated in countries that do not have
much experience with Internet-based treatment or psy-
chotherapy for depression, such as Poland and France, as
we do not know to what extent this type of treatment is
acceptable to patients and therapists in those countries.
From a research design perspective, the differences in
TAU between countries are challenging. In some coun-
tries, TAU may be primarily pharmacotherapy whereas in
other countries this may be CBT or combined treatment.
This is a pragmatic study, however, and where possible we
have standardized study procedures, inclusion and exclu-
sion criteria, outcome measures, and intervention compo-
nents while not restricting the content of TAU in any way.
The results will provide evidence-based recommenda-
tions for national and European mental health policy
and decision-makers allowing them to make informed
decisions regarding the dissemination and implemen-
tation of Internet-based treatments in primary and
specialized care, while taking into account the differ-
ent health care systems.
Trial status
The study commenced recruitment in February 2015
and is currently recruiting.
Additional files
Additional file 1: Figure 2. Schedule of enrolment, interventions, and
assessments in line with SPIRIT. (DOC 58 kb)
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